NEW YORK, June 9, 2026, 17:04 (EDT)
Hims & Hers Health shares rallied Tuesday, last quoted at $28.98, up about 6.6%, as investors returned to one of the year’s more volatile digital-health trades. The NYSE-listed company traded between $26.05 and $29.17 on volume of about 25 million shares, with a market value near $6.6 billion.
The move stood out because the broader market was not doing much helping. The Nasdaq fell 0.98% and the S&P 500 lost 0.27% as technology selling resumed; Michael O’Rourke, chief market strategist at JonesTrading, told Reuters: “When the bounce ran its course this morning, the tape came for sale more broadly.” Reuters
That matters now because Hims has become a live bet on whether online health platforms can sell weight-loss drugs at scale without giving up too much profit. GLP-1s, medicines used for diabetes and obesity treatment, have pulled Hims into a fight involving pricing, drug supply, compounding rules and the power of large drugmakers.
The company’s May quarter still hangs over the stock. Hims missed Wall Street estimates for first-quarter revenue and posted a surprise loss, with its move toward branded GLP-1 drugs weighing on margins and domestic sales. Chief Financial Officer Yemi Okupe said operating cash flow remained “the North Star” and said the company should be “well-positioned for profitability in 2027.” Reuters
Analysts framed the post-earnings selloff as an execution test, not simply a demand problem. “We view HIMS as an execution story now,” Jefferies analyst Brian Tanquilut said, while J.P. Morgan analyst Cory Carpenter pointed to a “compelling catalyst path” tied to a steadier weight-loss business, possible peptide legalization and faster second-half revenue growth. Reuters
The other piece is overseas growth. Hims said on June 2 it completed its acquisition of Eucalyptus, giving it a larger base across the U.S., UK, Australia and Canada, plus a growing presence in France, Germany, Ireland, Spain and Japan. CEO Andrew Dudum said the deal gave Hims the “foundation to become an everyday health companion,” while the company reiterated 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, a profit measure that strips out interest, taxes, depreciation and amortization and some other items. Hims Investors
Competitive pressure remains intense. Novo Nordisk agreed in March to sell Wegovy and Ozempic through Hims, ending a legal dispute over compounded weight-loss drugs, while Reuters said Novo still faces stiff competition from Eli Lilly, the market leader in obesity drugs. “While both parties lack trust, they remain bound by mutual necessity,” Truist analyst Jailendra Singh said at the time. Reuters
Hims’ own website now lists access to branded GLP-1 options including Novo’s Wegovy and Ozempic and Lilly’s Zepbound, with drug prices separate from the Hims weight-loss membership fee and prescriptions subject to clinical eligibility. The page also says Hims is not affiliated with or endorsed by Lilly.
The risk is that Tuesday’s move fades if branded drugs keep squeezing margins or if international expansion takes longer to pay off. Hims has warned that healthcare, privacy and drug rules are evolving across markets, and that restrictions on compounded GLP-1 products could disrupt operations, raise costs or hurt demand.
For now, the stock is moving as if investors are willing to look past the rough quarter and reprice the next stage of the story. That leaves a narrow path: Hims has to keep growth alive, handle the Eucalyptus integration, and prove the branded-drug pivot can make money rather than just lift traffic.
